Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Americas Cancer Immunotherapy Market Research Report, By Cancer (Prostate, Colorectal, Head & Neck Cancer), Therapeutics (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Vaccines), End Users (Hospitals, Academic Institutes) - Forecast till 2030

ID: MRFR/Pharma/0149-HCR | 90 Pages | Author: Kinjoll Dey| May 2024

Americas Cancer Immunotherapy Market Scenario:

The Americas cancer immunotherapy market is expected to reach USD 118274.96 Million by 2030 at 13.80% CAGR during the forecast period 2022-2030.Cancer Immunotherapy is a treatment that uses a person’s immune system to fight the diseases. Some types of the cancer immunotherapies are often referred to as biologic therapies or biotherapies. The basic principle of cancer immunotherapy is to enhance a patient’s immune system to fight against cancer. This can be achieved by administrating various immune system components, such as synthesized immune proteins. In recent years, cancer immunotherapy have been extensively exploited for the treatment of the different type cancers including breast, prostate, lung cancer, and others. Increasing prevalence of cancer is one of the major drivers for the Americas cancer immunotherapy market growth during the forecast period. The most commonly prevalent cancers in the U.S. include breast cancer, lung, bronchus cancer, and others. According to the National Cancer Institute in 2016, an estimated 1,685,210 new cases of cancer were diagnosed in the U.S. and approximately 595,690 people died due to cancer within the region. Moreover, growing geriatric population and rising healthcare expenditure will boost the market growth. Additionally, growing biotech and pharmaceutical industries fuels the market growth during the projected period. However, lack of awareness, restriction in therapeutics against different cancers and high cost for the treatment may restrain the market growth from 2022-2030. 

A cancer treatment called cancer immunotherapy improves the immune system's capacity to combat cancer. Because it offers long-term cancer security, has fewer adverse reactions, and heals a wider range of cancers, this therapy is better than the outdated method. Cancer immunotherapy tackles the infectious organisms that may cause cancer by inducing the development of antibodies, which is essential for the immune system's upkeep. Cancer immunotherapy is a novel form of treatment, but it has demonstrated remarkable promise in recent years. Additionally, the market is anticipated to increase rapidly throughout the projected period because of the substantial increase in cancer cases and current therapies' negative effects. In North America, a sophisticated healthcare system and increased government programs that offer favorable reimbursement policies are the main forces behind market expansion.

The market is thus anticipated to develop profitably throughout the forecast period due to the rising cancer burden and escalating R&D in various areas of cancer. Cancer immunotherapy is utilized for managing a variety of malignancies, including head and neck, melanoma, prostate, breast, colorectal, lung, and more. Immunotherapy mobilizes the immune system by activating the target and causing a reaction that can destroy cancer cells. This is how it works: guiding the immune system onto targets particular to cancer. Therefore, some mesothelioma patients have effectively had their life expectancy prolonged in clinical trials using immunotherapy medications like Keytruda, which is what is predicted. Thus, during the projected period, the market is anticipated to rise due to newer medicines' improving efficacy and precision and their reduced adverse effects compared to conventional chemotherapy.


A Fox Chase Cancer Center's Cancer Signaling and Microenvironment research program member recently received a $792,000 American Cancer Society scholarship grant to study cutting-edge lung cancer therapies. Prabha and colleagues will use the four-year award to create synthetic cellular targets for lung cancer immunotherapy. The novel practice of using medications, therapeutic vaccinations, antibodies, viruses, and cell-based therapies is known as immunotherapy. This procedure stimulates the body's immune system to recognize certain cancer cells and inhibit their growth.

October 2023 marked the Pan American Health Organization (PAHO)’s publication of a special issue dedicated to childhood cancer in the Pan American Journal of Public Health, commemorating the first five years since the WHO Global Initiative of Childhood Cancer (GICC) started in 2018. However, whilst children are sick with cancer, it will be an opportunity to pay tribute and honor those children throughout the world that have encountered cancer through this edition. In order to promote collaboration between key concerned parties aimed at combating childhood cancer, it tackles several aspects including: trends in mortality and incidence rates in Mexico City; progress made through national approaches such as the Brazil’s National Strategy (2009-2014); sub-regional initiatives like Central America’s Action Plan against non-communicable diseases; regional experiences such as efforts made by different countries concerning GICC’s impact within Latin America and Caribbean region; and finally joint global level programs among others.

Amgen announced today that its Biologics License Application (BLA) for tarlatamab was accepted by U.S. Food and Drug Administration (FDA), which also assigned Priority Review status on December 27th, 2023. Tarlatamab is a first-in-class investigational delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager therapy under development for advanced small-cell lung cancer patients who previously received platinum-based chemotherapy. Therefore, SCLC has only one pharmacological treatment modality currently available which has demonstrated limited efficacy due to tumor heterogeneity and rapid development of resistance mechanisms. Furthermore, if various options in term of dose regimen are tested simultaneously then its effectiveness can be assessed.

Preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) were announced by Eli Lilly and Company in March 2024 ahead of their presentation at American Association for Cancer Research (AACR) Annual Meeting which will be held on April 5-10 in San Diego. These will include the new fully human monoclonal anti-Nectin-4 antibody linked with a novel topoisomerase I inhibitor and an orally active, highly potent KRAS G12D inhibitor that is selective against wild-type KRAS among other presentations. An additional presentation will feature preclinical data related to an exceedingly strong and selective BRM (SMARCA2) inhibitor intended for treating cancers with BRG1 (SMARCA4) mutations in collaboration with Foghorn Therapeutics. The Investigational New Drug (IND) applications for all three programs are planned for 2024.

Intended Audience

  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers 

Figure 1:- Americas cancer immunotherapy market share, by region Americas cancer immunotherapy market

Sources: WHO, annual reports, press release, white paper, and company presentations


The Americas cancer immunotherapy market is segmented on the basis of cancer, therapeutics, and end users.

On the basis of the cancer, the Americas cancer immunotherapy market is segmented into lung cancer, prostate cancer, colorectal cancer, head & neck cancer, and others.

On the basis of the therapeutics, the Americas cancer immunotherapy market is segmented into monoclonal antibodies, immune checkpoint inhibitors, vaccines, non-specific cancer immunotherapies and adjuvants, and others. The monoclonal antibodies segment is sub segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, chemolabeled antibodies, bispecific monoclonal antibodies, and others. The naked monoclonal antibodies segment, by monoclonal antibody segment, is father segmented into alemtuzumab, trastuzumab, and others. The immune checkpoint inhibitors segment is sub segmented into PD-1 inhibitors, PD-L1 inhibitors, and others. The PD-1 inhibitors segment, by immune checkpoint inhibitors, is sub segmented into pembrolizumab, nivolumab, and others. The PD-L1 inhibitors segment, by immune checkpoint inhibitors, is further segmented into atezolizumab, avelumab, and others. The non-specific cancer immunotherapies and adjuvants segment is sub segmented into cytokines, interleukins, and others.

On the basis of the end users, the Americas cancer immunotherapy market is segmented as hospitals & clinics, academic institutes, research organization, and others. 


In a recent early-stage trial, 50% of patients with pancreatic cancer who received a tailored mRNA cancer vaccine following surgery did not experience a tumor recurrence one and a half years later. The trial, presented in a research paper reported in Nature, had a tiny patient population of only 16; therefore, it will need to be repeated in more extensive investigations. In recent research, the same mRNA technology employed to produce the incredibly effective COVID vaccinations targeted the patient's tumor neoantigens. BioNTech, a company that collaborated with Pfizer to develop one of the COVID vaccines, made the experimental vaccinations that Balachandran and his associates utilized. Sixteen patients received vaccinations from the researchers. After removing the tumors surgically, they administered mRNA vaccinations customized for each patient's

Regional Analysis 

On regional basis the Americas is divided into North America and Latin America. North America is sub segmented into U.S. and Canada. North America commands for the largest market share for the Americas cancer immunotherapy market due the presence of the U.S. within the region. This large share is also attributed due to the technologically advanced healthcare market in the region which is followed by high prevalence of cancer, increasing development in cancer immunotherapy treatment and rising per capita healthcare expenditure. Moreover, growing biotechnology, healthcare and life sciences sector within the region fuels the market growth regionally. The total number of the biotechnology industries in the U.S. increased from 2,763 in 2014 and reached 2,772 in 2015. Additionally, the abundance of state of the art laboratories in the U.S. is also facilitating the cancer immunotherapy market growth.

On the other hand, Latin America is the fastest growing region due to the presence of the developing economies within the region, rising healthcare expenditure and huge patient population. 

Research MethodologyAmerica Cancer Immunotherapy Market-

Sources: WHO, annual reports, press release, white paper, and company presentation

Key players for the Americas cancer immunotherapy market

Some of the major player in the Americas cancer immunotherapy market are Amgen Inc. (U.S.), AstraZeneca (U.K), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), and others.

Report Attribute/Metric Details
  Market Size   USD 118274.96 Million
  CAGR   13.80% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Cancer, Therapeutics & End Users 
  Geographies Covered   Americas 
  Key Vendors Amgen Inc. (U.S.), AstraZeneca (U.K), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland),
  Key Market Opportunities   Rising cancer burden and escalating R&D in various areas of cancer
  Key Market Drivers Growing geriatric population and rising healthcare expenditure will boost the market growth

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.